70.85USD-1.63%Mkt Cap: 6.12B USDP/E: —Last update: 2026-06-01
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humani…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap6.12B USD
Enterprise Value5.80B USD
Revenue (TTM)—
Gross Profit-190.44M USD
Net Income (TTM)-155.20M USD
Revenue/Share—
Last Price70.85 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees112
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-24.43
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B11.25
EPS (TTM)-2.12
EPS (Forward)-3.01
52W Range
13.9388% of range78.80
52W High78.80 USD
52W Low13.93 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-21.70%
ROA-19.95%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-169.25M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-1.23%
Net Debt-741.47M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio8.97
Quick Ratio8.80
Book Value/Sh6.532 USD
Cash/Share8.538 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateSep 8, 2023
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)95.20 USD
Target Range78.00 USD – 115.00 USD
# Analysts15
Ownership
Shares Out.86.84M
Float80.93M
Insiders5.90%
Institutions97.52%
Short Interest
Short Ratio9.2d
Short % Float15.31%
Short % Out.14.30%
Shares Short12.42M
Short (prev mo.)11.67M
Technical
SMA 5063.94 (+10.8%)
SMA 20036.60 (+93.6%)
Beta3.13
S&P 52W Chg27.70%
Avg Vol (30d)968.79K
Avg Vol (10d)940.44K
Technical Indicators
RSI (14)53.6
MACD2.0512
MACD Signal2.9159
MACD Hist.-0.8647
BB Upper78.05 USD
BB Middle72.85 USD
BB Lower67.66 USD
BB Width14.26%
ATR (14)3.844 USD
Vol Ratio (20d)0.18x